Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

Rediscovering citrate as a biomarker for prostate cancer

Nature Reviews Urology volume 21, pages 573–575 (2024)Cite this article

Subjects

For many years, PSA has been the most commonly used biomarker for prostate cancer screening and diagnosis. Although serum PSA measurement is highly sensitive, this biomarker has several limitations. Citrate, a molecule closely linked to the unique metabolism of prostate cancer, has the potential to be used as a complementary biomarker alongside PSA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Reprogramming of citrate metabolism during prostate cancer.

References

  1. James, N., Lee, N. & Horton, R. Announcing the Lancet Commission on Prostate Cancer. Lancet 397, 1865–1866 (2021).

    Article  PubMed  Google Scholar 

  2. Leslie, S. W., Soon-Sutton, T. L., Anu, R. I., Sajjad, H. & Skelton, W. P. Prostate Cancer. StatPearls [Internet] https://www.ncbi.nlm.nih.gov/books/NBK470550/ (updated 13 Nov 2023).

  3. Frégeau-Proulx, L. et al. Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion. Mol. Metab. 62, 101516 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bader, D. A. & McGuire, S. E. Tumour metabolism and its unique properties in prostate adenocarcinoma. Nat. Rev. Urol. 17, 214–231 (2020).

    Article  PubMed  Google Scholar 

  5. Kline, E. E. et al. Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection. J. Urol. 176, 2274–2279 (2006).

    Article  CAS  PubMed  Google Scholar 

  6. Gonthier, K. et al. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer. Mol. Oncol. https://doi.org/10.1002/1878-0261.13441 (2023).

  7. Costello, L. C., Franklin, R. B. & Feng, P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 5, 143–153 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Cooper, J. F. & Farid, I. The role of citric acid in the physiology of the prostate: a chromatographic study of citric acid cycle intermediates in benign and malignant prostatic tissue. J. Surg. Res. 3, 112–121 (1963).

    Article  CAS  PubMed  Google Scholar 

  9. Andersen, M. K. et al. Spatial differentiation of metabolism in prostate cancer tissue by MALDI-TOF MSI. Cancer Metab. 9, 9 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Gregório, E. P., Alexandrino, A. P., Schuquel, I. T. A., da Costa, W. F. & Rodrigues, M. A. F. Seminal citrate is superior to PSA for detecting clinically significant prostate cancer. Int. Braz. J. Urol. 45, 1113–1121 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology–Nephrology Research Axis, Centre de recherche du CHU de Québec, Université Laval, Québec City, Québec, Canada

    Lucas Galey & Étienne Audet-Walsh

  2. Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec City, Québec, Canada

    Lucas Galey & Étienne Audet-Walsh

  3. Centre de recherche sur le cancer de l’Université Laval, Québec City, Québec, Canada

    Lucas Galey, Hermann Nabi, Frédéric Pouliot & Étienne Audet-Walsh

  4. Department of Mechanical Engineering, University of Washington, Seattle, WA, USA

    Ayokunle Olanrewaju

  5. Department of Bioengineering, University of Washington, Seattle, WA, USA

    Ayokunle Olanrewaju

  6. Oncology Axis, Centre de recherche du CHU de Québec, Université Laval, Québec City, Québec, Canada

    Hermann Nabi & Frédéric Pouliot

  7. Departement of Social and Preventive Medicine, Faculty of Medicine, Université Laval, Québec City, Québec, Canada

    Hermann Nabi

  8. Laboratoire de recherche et d’innovation en médecine de première ligne (ARIMED), Groupe de médecine de famille universitaire de Saint-Charles-Borromée, CISSS Lanaudière, Saint-Charles-Borromée, Québec, Canada

    Jean-Sébastien Paquette

  9. VITAM Research Centre for Sustainable Health, Québec City, Québec, Canada

    Jean-Sébastien Paquette

  10. Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Université Laval, Québec City, Québec, Canada

    Jean-Sébastien Paquette

  11. Department of Surgery, Faculty of Medicine, Université Laval, Québec City, Québec, Canada

    Frédéric Pouliot

Authors
  1. Lucas Galey
    View author publications

    Search author on:PubMed Google Scholar

  2. Ayokunle Olanrewaju
    View author publications

    Search author on:PubMed Google Scholar

  3. Hermann Nabi
    View author publications

    Search author on:PubMed Google Scholar

  4. Jean-Sébastien Paquette
    View author publications

    Search author on:PubMed Google Scholar

  5. Frédéric Pouliot
    View author publications

    Search author on:PubMed Google Scholar

  6. Étienne Audet-Walsh
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Étienne Audet-Walsh.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Galey, L., Olanrewaju, A., Nabi, H. et al. Rediscovering citrate as a biomarker for prostate cancer. Nat Rev Urol 21, 573–575 (2024). https://doi.org/10.1038/s41585-024-00899-3

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41585-024-00899-3

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer